Topical Curcumin-Based Cream Is Equivalent to Dietary Curcumin in a Skin Cancer Model
Figure 3
Curcumin’s effects on the ERK pathway in vivo. (a) Western blot of pooled xenograft tumors () of the indicated antibody. (b) The presence and intensity of pERK staining (brown) in the control group compared to the presence and intensity of pERK staining in the curcumin-treated xenograft tumors. (c) Representative IHC staining of SRB-12 p9 WT cell tumor xenografts. Paraffin sections of tumors were probed with STAT3 phospho-Tyr705 (pSTAT3, top row) or ERK1/2 phospho-Thr202/Tyr204 (pERK, bottom row), followed by an Alexa546-labeled secondary antibody (400x). (d) IL-6 ELISA of pooled mouse serum () in duplicate.
